@ASMBS updated position statement on bariatric surgery in class I obesity for patients with BMI 30 -35.
What more evidence we need before we can provide the right treatment to our patients suffering from #diabesity ?
Bariatric surgery is not simply weight loss surgery!
New @asmbs position statement in class I obesity (BMI 30-35) supported by @AmDiabetesAssn endorsed by @SAGES_Updates https://t.co/LaBJWx6Xlq
1.#BariatricSurgery considered w/ comorbidities and nonsurgical treatments failure
2.#MetabolicSurgery strongly considered w/T2 diabetes
#metabolicsurgery is no less than any other field in level 1 data!
11 randomized clinical trial looking into the differences between 2 great operations #sleevegastrectomy and #gastricbypass both already proven superior to medical therapy with level 1 data
@NeilFlochMD@ASMBS
11 Randomized Clinical Trials:
1. Bypass and Sleeve are equivalent for weight loss and Diabetes resolution.
2. Sleeve has less complications and reoperation rate than Bypass.
3.Bypass may be superior in dyslipidemia, hypertension and reflux remission.
@o_m_ghanem @NeilFlochMD@ASMBS Anecdotally, this is exactly what I see in my practice. Of course we are careful not to make anecdotal decisions due mainly to challenging follow up
@LutfiForward and @JaimePonceMD sharing insights on role of industry, the growth of bariatric endoscopy, the growth and decline of specific bariatric procedures, and the future of revisional bariatric surgery https://t.co/GfKZkrCvBm @MISSconference@colleenhutch@ASMBS
@ASMBSFoundation supports research, education, awareness and access for patients suffering the disease of obesity ... become an AWARE supporter https://t.co/wb7uVUDOec @LutfiForward